A phase III randomized, controlled trial of Myocet®, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first-line therapy of metastatic breast cancer
MYOCET PHASE III
Clinical Trial Program
A phase III randomized, controlled trial of Myocet®, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first-line therapy of metastatic breast cancer
Phase II
Status
Finished
Tumour subtype:
HER2+
Scenario
Localmente avanzado o metastático
Sites
